ANIP
ANI Pharmaceuticals Inc
74.00$
-0.5%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +1.6% | +1.1% | +0.7% | +39.8% | -0.3% | +0.7% | +3.9% | +4.9% | +2.3% | -1.3% | +5.1% | |
| – | +4.5% | +4.0% | +2.8% | -6.2% | +1.2% | +1.6% | +12.4% | +15.9% | +7.8% | -0.8% | +10.5% | |
| – | +14.5% | +3.4% | +5.0% | -39.6% | -0.1% | +3.4% | +45.4% | +20.6% | +8.7% | +9.0% | +15.8% | |
| – | +14.5% | +7.7% | +3.7% | -38.0% | -1.4% | +2.7% | +44.0% | +17.5% | +8.7% | +9.0% | +20.8% | |
| – | -9.4% | +6.4% | -3.7% | +18.2% | +12.9% | -0.6% | +2.4% | +11.9% | +11.3% | -9.1% | +7.5% | |
| – | +4.3% | +2.4% | +10.2% | +18.0% | -7.6% | +0.5% | +0.7% | +5.9% | -2.3% | +0.3% | -0.2% | |
| – | +0.0% | +0.0% | +0.0% | +114.1% | -0.7% | +1.1% | -0.2% | +3.2% | +0.0% | +0.0% | +0.0% | |
| – | -4.9% | -6.2% | -6.6% | +211.2% | -4.9% | -0.6% | -3.4% | -3.9% | -4.1% | -2.6% | -3.7% | |
| – | +8.4% | -1.9% | -4.8% | +94.6% | -0.2% | -0.7% | +3.8% | +2.4% | -0.3% | -4.4% | +4.3% | |
| – | +8.3% | -5.9% | +2.3% | +35.7% | +2.0% | +4.2% | +17.4% | +14.2% | +2.8% | -13.9% | +18.4% | |
| – | +0.0% | +0.0% | +0.0% | +741.4% | +28.2% | +22.0% | +18.1% | +15.3% | +13.3% | +11.8% | +10.5% | |
| – | +7.6% | +34.7% | -1.5% | +25.1% | -25.0% | +16.2% | +2.8% | +27.9% | -10.3% | +11.4% | +5.9% | |
| – | -0.1% | -0.1% | -0.1% | +117.4% | -0.5% | -0.5% | -0.5% | -0.5% | -0.9% | -0.9% | -0.9% | |
| – | -4.8% | +4.4% | +6.3% | -10.4% | -0.5% | +3.5% | +4.1% | +9.6% | +6.9% | +4.0% | +6.2% | |
| – | – | – | – | – | – | – | – | – | – | – | +386.5% | |
| – | +0.5% | +1.1% | -0.5% | +0.4% | +0.2% | +3.1% | +1.3% | +3.9% | +0.6% | +1.5% | +1.7% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.